Management of Patients with Cystic Fibrosis and ABPA using Anti-IgE therapy (Omalizumab).
| dc.contributor.author | ElMallah, Mai | |
| dc.contributor.author | Hendeles, Leslie | |
| dc.contributor.author | Schuler, Pamela | |
| dc.contributor.author | hamilton, robert | |
| dc.contributor.author | capen, cindy | |
| dc.date.accessioned | 2021-11-01T14:25:48Z | |
| dc.date.available | 2021-11-01T14:25:48Z | |
| dc.date.updated | 2021-11-01T14:25:48Z | |
| dc.identifier.uri | ||
| dc.publisher | Pediatric Pharmacy Advocacy Group | |
| dc.relation.ispartof | J Pediatr Pharmacol Ther. | |
| dc.title | Management of Patients with Cystic Fibrosis and ABPA using Anti-IgE therapy (Omalizumab). | |
| dc.type | Journal article | |
| pubs.begin-page | 88 | |
| pubs.end-page | 92 | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Cell Biology | |
| pubs.organisational-group | Neurobiology | |
| pubs.organisational-group | Pediatrics, Pulmonary and Sleep Medicine | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Pediatrics | |
| pubs.organisational-group | Clinical Science Departments |
Files
Original bundle
1 - 1 of 1